Generic Name and Formulations:
Ganciclovir 4.5mg; per implant; for intravitreal implantation.
Bausch Health Companies Inc.
Indications for VITRASERT:
Treatment of cytomegalovirus (CMV) retinitis in patients with AIDS.
Adults and Children:
<9yrs: not recommended. ≥9yrs: Implant designed to release drug over 5–8 months. May be removed and replaced following depletion of ganciclovir.
External infection. Severe thrombocytopenia.
Should be administered by surgeon who has observed or assisted in surgical implantation of Vitrasert prior to attempting procedure. Monitor for extraocular CMV disease. Ophthalmologic follow-up advised at appropriate intervals. Pregnancy (Cat.C). Nursing mothers: not recommended.
Visual acuity loss of 3 lines or more, vitreous hemorrhage, retinal detachments, cataract formation/lens opacities, macular abnormalities, intraocular pressure spikes, optic disk/nerve changes, hyphemas, uveitis.
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Congress Passes Bill to Fight Opioid Crisis
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure